We use necessary cookies to make our website work. We'd also like to use optional analytics cookies to help us improve it.
For more information, please read our cookie policy.

UK – EU Transition, and UK Civil Aviation Regulations

To access current UK civil aviation regulations, including AMC and GM, CAA regulatory documents, please use this link to UK Regulation. Please note, if you use information and guidance under the Headings below, the references to EU regulations or EU websites in our guidance will not be an accurate information or description of your obligations under UK law. These pages are undergoing reviews and updates.

Amiodarone:

Class 1 - Amiodarone is unacceptable for Class 1 medical certification.

Class 2 - Usually requires a VCL (day time flying only) limitation. If the applicant does not experience glare at night (usually noticed when they are driving) then, subject to a satisfactory AMS ophthalmological review, unrestricted Class 2 medical certification may be possible (i.e. night flying is permitted).

See also Atrial Fibrillation (PDF) flow chart

Flecainide:

Flecainide, used for the treatment of atrial fibrillation, may be acceptable. Some patients experience mild ocular side effects. Most commonly, up to 14% of patients may develop small corneal deposits1. These are asymptomatic and usually have no implications for vision1,2. Less commonly, mild blurry vision on extreme lateral gaze may occur due to an effect on the vestibular apparatus2, rather than on the eye itself. Pilots complaining of blurred vision on lateral gaze who found to have nystagmus should undergo tests of vestibular function2 rather than further ophthalmological review.

No studies have shown abnormal visual function with Flecainide. Ophthalmological review is only indicated if reduced visual function is clinically indicated; there is no case for routine ophthalmological screening of pilots on Flecainide.

Note: Flecainide is not acceptable for certification if used for the treatment of ventricular arrhythmias even in a structurally normal heart; Medical Advisory Panel recommendation (2006).


References

1. Moller HU, Thygesen K, Kruit PJ. Corneal deposits associated with flecainide. BMJ 1991; 302 (6775): 506-7
2. Ikaheimo K, Kettuven R, Montyjarvi M. Adverse ocular effects of flecainide. Acta Ophthal Scand 2001; 79 (2): 175-6

Provide page feedback

Please enter your comments below, or use our usual service contacts if a specific matter requires an answer.

Fields marked with an asterisk (*) are required.

Latest from UK Civil Aviation Authority

  1. 2022 quarter one flight data
  2. Continued focus on change for GA Team
  3. Virtual aviation work experience partnership with Springpod

View all latest news